BioSpace News Archive

Q1 2021 Adjusted Total Revenue - $14.5 million - - Q1 2021 Adjusted EBITDA - $4.4 million - - Blexten Canadian Prescriptions Increased 22% Year-Over-Year - - Cambia Canadian Prescriptions Increased 9% Year-Over-Year - Miravo to Hold Virtual Annual Meeting May 17th at 9:00 a.m. ET

Strategic credit financing agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”) will provide up to $125 million to support continued development and commercial readiness of both the oral and IV ganaxolone programs

Incyte (Nasdaq:INCY) today announced positive topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Names (USAN) Council has officially designated the Companys long-acting injectable glucagon-like peptide-1 (GLP-1) receptor agonist drug candidate for short bowel syndrome, NM-002

Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit and present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit.

Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announces a shareholder message from the CEO.

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF)(“Predictmedix” or the “Company”) is pleased to announce that Safe Entry Station units will be deployed at the North American tour of Hockeyfest in partnership with Juiceworks Exhibits (JUICEWORKS) and Jones Entertainment Grou

Deerfield Management Company, a healthcare investment management firm focused on advancing healthcare through investment, information and philanthropy, and Baylor College of Medicine announced a major research collaboration to advance promising therapeutics and support pharmaceutical research and discovery.

Imbria Pharmaceuticals today announced that IMB-101, a novel partial fatty acid oxidation (pFOX) inhibitor designed to shift myocardial substrate utilization in favor of glucose oxidation to increase the efficiency of mitochondrial energy generation, was well tolerated in a Phase 1 study of healthy volunteers.